Aim: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazineinduced EPS in schizophrenic patients. Methods: We identified seven SNP(single nucleotide polymorphism) TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction) . Results: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups. Conclusion: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
Introduction
Schizophrenia is a complex and devastating brain disorder that affects 1% of the population and is ranked as one of the most costly disorders to afflict humans [1] . Chlorpromazine is a typical antipsychotic drug used for the treatment of schizophrenia since the 1950s, and became a milestone in the development of treatments for psychotic disorders. Although chlorpromazine is no longer used in some countries, it is still widely used to treat schizophrenia in China and many other developing countries. During the treatment of schizophrenics with antipsychotics, especially the typical antipsychotics, it can cause a high rate of extrapyramidal syndrome (EPS), including akathisia, acute dystonia and pseudoparkinsonism, and tardive dyskinesia, which is a serious drawback in neuroleptic treatment. However, the occurrence of EPS can be the bottleneck of chlorpromazine treatment.
In recent years, investigators have been trying to find genetic factors contributing to drug-induced EPS by paying close attention to dopamine receptor genes. Ser9Gly polymorphism in DRD3 was studied extensively and inconsistent reports were published [2] [3] [4] . In addition, several studies have aimed to identify the relationship between the DRD2 gene polymorphisms and the drug response or adverse effects, but the results are also controversial [5] [6] [7] . Two studies revealed that TaqIA and -141Cins>del were associated with drug response [6, 7] , but one showed a negative associaKey words dopamine receptors; basal ganglia disease; polymorphism; chlorpromazine; schizophrenia 1 Project supported by grants from the national 973 and 863 programs, the National Natural Science Founda ti on of China, a nd t he Shanghai Municipal Commission for Science and Technology. 6 These authors contributed equally to this work. 7 Correspondence to Prof Lin HE. Ph n 86-21-6282-2491. Fax 86-21-6282-2491. E-mail helin@sjtu.edu.cn tion [2] . Meanwhile, an in vitro study demonstrated that the -141Cins>del polymorphism had a functional role in affecting DRD2 expression [8] . In addition, Ser311Cys polymorphism partly affected the neuroleptics binding affinity to cause the blockade of functional activity [9] . Hence, DRD2 is likely to be a promising candidate gene for the inducement of EPS in schizophrenic patients. In our previous study, we found that -141Cins>del in the DRD2 gene may be related to the therapeutic effects of chlorpromazine in schizophrenic patients [10] . The dopamine D2 receptor (DRD2) is the primary binding target of all antipsychotics. It belongs to the family of receptors coupled to heterotrimeric cyclic guanine nucleotide binding regulatory proteins (G-proteins). DRD2 activates intracellular signaling by the inhibition of cAMP synthesis through interaction with G 1 -like proteins [5] . The development of EPS has been seen as a consequence of the action of typical neuroleptics on striatal DRD2. Dopamine receptor blockade in the basal ganglia is considered as the mechanism of EPS [11] .
Farde et al [12] [13] [14] [15] , in a series of studies, have shown that: (1) typical neuroleptics from different chemical classes used at conventional doses occupy 65%-89% of the available DRD2; and (2) individuals who experience EPS have significantly higher (82%±4%) levels of DRD2 blockade as compared to those patients without EPS (74%±4%). Otherwise, clozapine, an atypical neuroleptic, has a significantly lower level of DRD2 occupancy and produces virtually no EPS at conventional doses [16] . Another study has also reported a consistent result [17] . The degree of DRD2 occupancy can be an indicate of EPS [18] . All of the above suggests that DRD2 is closely related to the onset of EPS.
In order to evaluate whether variations in the DRD2 gene are related to drug-induced EPS, we identified more SNP (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene of 146 Chinese schizophrenic inpatients treated with chlorpromazine.
Materials and methods

Patients and drug treatment
We recruited 146 patients, who were of Han Chinese origin, from Shanghai Mental Health Center. Informed consent was obtained from all participating patients. All patients were acute inpatients with schizophrenia (mean age of onset=27.3 years, SD=9.2, 38.7% female) diagnosed according to Diagnostic and Statistical Manual of Mental Disorder, Third Edition, Revised (DSM-III-R) [19] . None of the patients had any medication for at least 1 month before this study. The dosage of chlorpromazine used in the comparison study was in a range of 300-600 mg/d. Patients treated with any other antipsychotic drugs were not included. The diagnosis for each patient with EPS was made in terms of the Simpson-Angus Scale (SAS) by at least two psychiatrists, independently, after the patients were treated with chlorpromazine for 8 weeks. As a result, 59 of 146 patients experienced EPS. The participating psychiatrists were blinded to the patients' genotypes.
SNP genotyping We chose 7 SNP (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 from http://www.ncbi.nlm. nih.gov/SNP/ and TaqIA) from DRD2, which spans about 270 kb where -141Cins>del is in the promoter region, TaqIB and TaqID are in intron 1 and intron 2, rs6275 and rs6277 are in exon 7. TaqIA is in the 3'-untranslated region, which is in fact located in a novel gene, untitled X-kinase gene [20] . Genomic DNA was extracted from peripheral blood leukocytes by a standard phenol extraction procedure.
Genotyping of TaqIB, TaqID and TaqIA was modified on the basis of Kaiser et al [5] , while analysis of -141Cins>del was modified according to Jönsson et al [21] . Rs6275 and rs6277 were analyzed by direct sequencing. All amplification reactions were performed in a total volume of 25 µL, containing 10 ng DNA, 1×buffer, 200 µmol/L dNTP, 4×10 -6 µmol/L of each primer, 1×Q solution, and 1 unit Taq DNA polymerase.
The PCR program of all these reactions consisted of 36 cycles, including an initial denaturation at 94 ºC for 5 min, and a terminal extension period at 72 ºC using a Gene Amp 9700 thermcycler (Applied Biosystems, Foster City, CA). The condition of the cyclic PCR was as follows. All but rs6275 and rs6277 PCR products were digested with restriction enzymes according to the manufacturer's protocol, separated by 2.0% agarose gel electrophoresis and stained with ethidium bromide for UV visualization. For rs6275 and rs6277, we first amplified a fragment including the two SNP, and then purified the PCR product with shrimp alkaline phosphatase. The purified PCR product was used to carry out sequencing reaction by using sense primer and a BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) as a total volume of 5 µL. The sequence analysis was performed in an ABI PRISM model 3100 DNA sequencer (Applied Biosystems, Foster City, CA).
Statistical methods The difference of allele distribution between patients with EPS and without EPS was investigated using CLUMP version 1.6 [22] based on 1000 stimulations. The P-values reported were two tailored and the limit of significance was set to 0.05. The pair-wise linkage disequilibrium (LD), as measured by D' [23] , was estimated with 2LD software from haplotype frequencies based on alleles at all possible pairs of SNP loci [24] . EHPLUS was used to estimate the haplotype frequency by performing model-free analysis and permutation tests of allelic association based on EH [25] . It uses marker genotypes from a group of unrelated individuals or a group of cases and a group of controls and employs gene-counting algorithm to estimate haplotype frequencies and output asymptotic and permutation test statistics. We used an online calculator to test the departure from Hardy-Weinberg equilibrium in both groups (Online Hardy-Weinberg equilibrium calculator http://www.kursus. kvl.dk/shares/vetgen/ Popgen/genetik/applets/kitest.htm).
Results
Extensive genetic variations, including restriction sites TaqIB, TaqIA, and rs6275, exist in the DRD2 gene of schizophrenics. However, TaqID,Ser311Cys with an amino acid substitution and rs6277 showed low frequency of variation in the subjects. Frequencies of all SNP genotypes revealed no significant deviation from Hardy-Weinberg equilibrium. The result of analysis of the SNP by CLUMP is presented in Table 1 . No statistical significance between 59 patients with EPS and 87 patients without EPS was observed in both genotype and allele distribution on each single marker.
The results showed that TaqIB, rs6275, and TaqIA were in relative strong linkage disequilibrium, or in a LD block. The frequency of any two haplotypes consisting of the three SNP in linkage disequilibrium had no statistical difference (data not shown).
Discussion
It is generally recognized that genetic variants in DRD2 are promising as predictors for adverse affects of antipsychotic medication in schizophrenia patients, including EPS. Many studies have reported on the relationship between the DRD2 gene and the occurrence of schizophrenia and drug response in schizophrenia, but few have reported on the correlation between SNP in DRD2 and response to chlorpromazine, which is widely and routinely used in China and developing countries. In this work, however, we genotyped 7 SNPs, including -141Cins>Del, TaqIA, TaqIB, Ser311Cys, rs6275, rs6277, and TaqID, but only four of them were informative enough to carry out statistical analysis. The results showed no statistical differences in allele and genotype frequency of -141Cins>del, TaqIB, rs6275, and TaqIA (P>0.05). A strong level of LD was detected in TaqIB, rs6275, and TaqIA (D'>0.5). No significant difference was [8] and Mihara et al [26] , who found a positive association between the polymorphisms in DRD2 and EPS, but more agreeable with other more comprehensive studies that show no association between the polymorphisms of DRD2 and EPS in Caucasian people [5, 27, 28] . In our study, as only one drug was used and patients had no other medication at least one month before this study, the detecting power was much higher than using different neuroleptics. In addition, relatively large sample sizes and more polymorphisms were analyzed in our study and that of Kaiser et al [5] , although both showed negative results. The mechanism of EPS is more complex than its phenotype. Although the D2 receptor is shown to have a direct effect on the inducement of EPS, the polymorphisms themselves in DRD2 gene do not play a major role. Instead, they may cause EPS during medication with antipsychotics by interaction with other genes, which code drug metabolizing enzymes and other receptors, such as CYP2D6 and DRD3. Moreover, the impact of polymorphisms in DRD2 is not large enough for detection using the current method, but the effect may become obvious in specific gene-gene and gene-environment interactions. So, we cannot exclude a role of DRD2 in further pharmacogenetic and pharmacogenomic studies.
One negative factor of the present study is that the diagnosis of the patients with EPS recruited was made after 8 weeks of treatment with chlorpromazine, which was relatively short. The variations in DRD2 analyzed here affected lateonset EPS after long-term treatment but had little effect on early-onset EPS. Chen et al [28] showed that TaqIA polymorphism was associated with the occurrence of tardive dyskinesia after long-term treatment.
In conclusion, DRD2 is the rational candidate gene as a predictor of the neurological adverse effects from treatment with antipsychotic drugs. However, the 4 genetic variants in the DRD2 gene analyzed here have not been shown to play a major role in the inducement of EPS in Chinese schizophrenic patients. In our further study, more relative genes, such as DRD3, will be studied to clarify this and the interaction of the genes involved will also be investigated.
